MarketBeatSat, 16 May 2026 10:08:49 GMTDenali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome ApprovalDNLI-3.97%
Seeking AlphaWed, 13 May 2026 02:00:48 GMTDenali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 TranscriptDNLI-3.97%
Seeking AlphaSun, 03 May 2026 04:13:00 GMTDenali: The First Commercial Validation Of The Blood-Brain Barrier PlatformDNLI-3.97%
Zacks Investment ResearchFri, 17 Apr 2026 18:40:25 GMTDNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?DNLI-3.97%
Zacks Investment ResearchTue, 07 Apr 2026 19:31:13 GMTDenali Stock Falls as Partner Takeda Ends Collaboration DealDNLI-3.97%
Investors Business DailyWed, 01 Apr 2026 12:00:50 GMTDenali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.DNLI-3.97%
Zacks Investment ResearchThu, 26 Mar 2026 19:26:06 GMTDenali Wins FDA Nod for Hunter Syndrome Drug, Stock UpDNLI-3.97%
Seeking AlphaThu, 26 Mar 2026 10:55:55 GMTDenali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome TranscriptDNLI-3.97%
Investors Business DailyWed, 25 Mar 2026 18:08:17 GMTDenali Jumps, Pulling Regenxbio Higher, On Early FDA ApprovalDNLI-3.97%
Seeking AlphaSat, 21 Mar 2026 00:22:22 GMTDenali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum TranscriptDNLI-3.97%
Zacks Investment ResearchWed, 11 Mar 2026 16:35:33 GMTDenali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?DNLI-3.97%
Seeking AlphaFri, 06 Mar 2026 20:55:57 GMTDenali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference TranscriptDNLI-3.97%
Zacks Investment ResearchFri, 27 Feb 2026 15:06:15 GMTDNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in FocusDNLI-3.97%
